Imperial College London


Faculty of MedicineDepartment of Surgery & Cancer




+44 (0)20 3313 3759eric.aboagye




Mrs Maureen Francis +44 (0)20 7594 2793




GN1Commonwealth BuildingHammersmith Campus





Eric Aboagye is Professor of Cancer Pharmacology & Molecular Imaging and Director of the CRUK-EPSRC-MRC-NIHR Comprehensive Cancer Imaging Centre. He joined the college after a PhD at the CRUK Beatson Laboratories in Glasgow, UK and post-doc fellowship at The Johns Hopkins University & Hospital in Baltimore, USA. His group is interested in the discovery and development of new methods for experimental and clinical cancer molecular imaging. In the past 5 years, the team has invented and translated three novel cancer diagnostics into human application. He has acted as an advisor to GE-Healthcare, GSK, Roche and Novartis.

Professor Aboagye was recipient of the 2009 Sir Mackenzie Davidson Medal and was  elected as a Fellow of the Academy of Medical Sciences in 2010. Academy Fellows are elected for outstanding contributions to the advancement of medical science, for innovative application of scientific knowledge or for conspicuous service to healthcare.



Aboagye EO, PET imaging of small animals in anticancer drug development, Molecular Imaging in Biology, Vol:7, Pages:53-58

Rupniewska E, Roy R, Mauri FA, et al., 2018, Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors., Oncotarget, Vol:9, Pages:27346-27362

Kramer GM, Liu Y, de Langen AJ, et al., 2018, Repeatability of quantitative F-18-FLT uptake measurements in solid tumors: an individual patient data multi-center meta-analysis, European Journal of Nuclear Medicine and Molecular Imaging, Vol:45, ISSN:1619-7070, Pages:951-961

Heinzmann K, Nguyen Q-D, Honess DJ, et al., 2018, Depicting changes in tumor biology in response to cetuximab mono- or combination therapy by apoptosis and proliferation imaging using 18F-ICMT-11 and 3'-Deoxy-3'-[18F]Fluorothymidine (18F-FLT) PET., J Nucl Med


Patel H, Periyasamy M, Sava GP, et al., 2018, ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment, UK Breast Cancer Research Symposium, AMER ASSOC CANCER RESEARCH, Pages:1156-1166, ISSN:1535-7163

More Publications